Table 2.
Clinical presentation of gemcitabine‐associated thrombotic microangiopathy in the 120 patients
| Patients (n = 120) | ||
|---|---|---|
| Duration of treatment (days; n = 109) | 210 (120–256) | |
| Cumulative dose (mg m –2 ; n = 32) | 12 941 (6303–17 647) | |
| Clinical symptoms | (n = 111) | |
| Oedema | 56.7% | |
| Hypertension | 62.2% | |
| Neurological signs | 9.9% | |
| Digestive symptoms | 9% | |
| Fever | 7.2% | |
| Sepsis concomitant | 2.7% | |
| Arthralgia | 0.9% | |
| Purpura | 6.3% | |
| Haematological characteristics | Haemolytic anaemia | 95.6% (110/115) |
| Thrombocytopenia | 74.6% (85/114) | |
| Platelet (109 l–1; n = 74) | 65.5 (35–104) | |
| Schizocytes | 55.3% (57/103) | |
| Renal characteristics | AKI | 97.4% (113/116) |
| Creatinine at the time of diagnosis (n = 86) | 204.5 (135–325) | |
| Need for renal replacement therapy | 27.8% (27/97) | |
| Haematuria | 22.8% (26/114) | |
| Proteinuria | 34.2% (39/114) | |
| Proteinuria (g/24 h; n = 28) | 1.4 (0,6‐2,86) | |
| Kidney biopsy | 20% (23/115) | |
Quantitative variables are expressed as median with interquartile ranges. All qualitative variables are expressed as percentages calculated among patients for whom the information was available, therefore excluding the missing data. AKI, acute kidney injury